Bain Capital injects up to $300 million in Cardurion Pharmaceuticals

Bain joins existing investors Takeda Pharmaceuticals and Polaris Partners in supporting the evolution of the cardiovascular biotechnology company.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this